"Ua matou iloa mai le matou faʻaogaina o le DBS mo le toeitiiti atoa le luasefulu tausaga e togafitia ai faʻafitauli faʻaletonu e pei o le Parkinson ma le gatete taua o le faʻatinoga o se togafitiga saogalemu ma masani ona talia lelei," o le tala lea a Dr. Whiting. E sili atu nai lo le 160,000 tagata i le lalolagi atoa ua maua togafitiga DBS mo na tulaga.

O le AHN o se tasi lea na o le 20 nofoaga i le Iunaite Setete ua filifilia e auai i le ADvance II Study lea o loʻo faʻatautaia foi i Kanata ma Siamani.

O le fa'ama'i o le Alzheimer o le fa'ama'i taatele lea o le tu'inanau. E tusa ma le 6.2 miliona, poʻo le tasi i le iva tagata Amerika e 65 tausaga ma matutua atu o loʻo nonofo ma Alzheimer; 72 pasene e 75 tausaga pe sili atu. O le fa'ama'i o le Alzheimer ose fa'ama'i fa'agasolo ma i lona fa'ai'uga, e a'afia ai neu i vaega o le fai'ai e mafai ai e le tagata ona fa'atino galuega fa'aletino, e pei o le savali ma le foloina. O le fa'ama'i e i'u lava ina oti ma e leai se vaifofo.

O le DBS mo le Alzheimer e aofia ai le faʻaogaina o se masini faʻapipiʻi e pei o le fatu pacemaker ma lua faʻapipiʻi uaea e tuʻuina atu saʻo eletise eletise i se vaega o le faiʻai e taʻua o le fornix (DBS-f), lea e fesoʻotaʻi ma le manatua ma le aʻoaʻoina. O le fa'aosofiaga eletise e talitonuina e fa'agaoioi ai le fa'asologa o manatuaga i totonu o le fai'ai e fa'amalosi ai lana galuega.

O suʻesuʻega faʻapitoa, faʻalua-tauaso e fa tausaga mo tagata auai, e tofu i latou ma se suʻesuʻega faʻataʻitaʻiga a le Alzheimer aʻo leʻi faʻapipiʻiina le neurostimulator. O faʻaiʻuga o lenei suʻesuʻega faʻaletino, mafaufau, ma le mafaufau o le a faʻaaogaina e fai ma fua faʻavae aʻo suʻesuʻeina masani mo le fua o le alualu i luma o le Alzheimer i le umi o le suʻesuʻega.

A maeʻa le faʻapipiʻiina, o le lua vaetolu o tagata mamaʻi o le a faʻafuaseʻi ona faʻagaoioia a latou neurostimulator ma o le tasi vaetolu o le a tuʻu a latou masini. O ma'i e pe le masini ile amataga ole su'esu'ega ole a fa'agaoioi ile 12 masina.

I le taimi atoa o le faʻataʻitaʻiga o le falemaʻi, o tagata suʻesuʻe o le a mataʻituina e se vaega multidisciplinary o AHN neurologists, psychiatrists ma neurosurgeons, e aofia ai Dr. Whiting ma le uso a AHN neurosurgeon ma le DBS specialist Nestor Tomycz, MD.

Ina ia agava'a mo le fa'amasinoga, e tatau ona 65 tausaga pe sili atu fo'i tagata mama'i, e maua i le ma'i vaivai o le Alzheimer, o lo'o lelei lona soifua maloloina, ma ia iai se tausi ma'i po'o se tasi o le aiga na te fa'atasi ma i latou i asiasiga a foma'i.

"O taunuʻuga o vaega muamua o lenei faʻataʻitaʻiga faʻataʻitaʻiga o loʻo faʻamaonia ma faʻaalia ai le togafitiga e mafai ona faʻamanuiaina ai tagata mamaʻi maʻi Alzheimer e ala i le faʻamautuina ma le faʻaleleia o latou gaioiga mafaufau," o le tala lea a Dr. Whiting. "O le taʻua o se taunuuga manuia o lenei suʻesuʻega e mafai ona suia ai olaga mo le faitau miliona o tagata Amerika e aʻafia i lenei faʻamaʻi faʻavaivaia, faʻamaʻi oti e le o se faʻamatalaga. Matou te fiafia lava i le i ai o se tasi o vaega iloga o taotoga i le lalolagi o loʻo ofoina atu i tagata maʻi o Alzheimer le avanoa i lenei faʻafouga.

I lalo o le taʻitaʻiga a Dr. Whiting, AHN's Allegheny General Hospital ua leva ona taʻimua i taumafaiga paionia e faʻalautele le faʻaogaina o le faʻaosofia o le faiʻai loloto. O le falemaʻi o le muamua lea i sisifo o Penisilevania na faʻaogaina le tekinolosi e togafitia ai le gaʻo taua ma le maʻi o Parkinson, ma talu ai nei, na amata ai e Dr. Whiting ma lana 'au le vaega lona lua o se suʻesuʻega faʻapitoa e suʻesuʻe ai le aoga o le DBS e fesoasoani i le puleaina o le tino puta.

OA MEA E AVEA MAI LENEI TUSI:

DBS for Alzheimer’s involves the use of an implanted device similar to a heart pacemaker and two attached wires that deliver mild electrical pulses directly to an area of the brain called the fornix (DBS-f), which is associated with memory and learning.
Alzheimer’s is a progressive disease and in its late stages, the neurons in parts of the brain that enable a person to carry out basic bodily functions, such as walking and swallowing are affected.
The results of this physical, psychological, and cognitive evaluation will be used as a baseline measurement as they are regularly assessed for the rate of Alzheimer’s progression throughout the duration of the study.